[HTML][HTML] Apixaban to prevent venous thromboembolism in patients with cancer
M Carrier, K Abou-Nassar, R Mallick… - … England Journal of …, 2019 - Mass Medical Soc
Background Patients with active cancer have an increased risk of venous thromboembolism,
which results in substantial morbidity, mortality, and health care expenditures. The Khorana …
which results in substantial morbidity, mortality, and health care expenditures. The Khorana …
[HTML][HTML] Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial
RD McBane, WE Wysokinski, J Le-Rademacher… - Blood, 2018 - Elsevier
Background: Currently, low molecular weight heparin is the guideline endorsed treatment of
patients with cancer associated venous thromboembolism (VTE). While apixaban is …
patients with cancer associated venous thromboembolism (VTE). While apixaban is …